Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer

Abstract Objective The principal objective of this study is to clarify the prognostic significance of borderline resectable pancreatic cancer (BRPC). The second objective is to evaluate the prognostic impact of the depth of pathological venous invasion. Methods The study included 122 pancreatic canc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of surgical oncology 2017-06, Vol.43 (6), p.1068-1075
Hauptverfasser: Hoshimoto, Sojun, Hishinuma, Shoichi, Shirakawa, Hirofumi, Tomikawa, Moriaki, Ozawa, Iwao, Wakamatsu, Saho, Hoshi, Sayuri, Hoshi, Nobuo, Hirabayashi, Kaoru, Ogata, Yoshiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Objective The principal objective of this study is to clarify the prognostic significance of borderline resectable pancreatic cancer (BRPC). The second objective is to evaluate the prognostic impact of the depth of pathological venous invasion. Methods The study included 122 pancreatic cancer patients who underwent curative surgery. All computed tomography scans of the patients were retrospectively interpreted and classified according to the NCCN guidelines, version 1.2016, as resectable (-) or borderline resectable (+) in each arterial (BR-A) and venous (BR-PV) involvement. Results The overall survival (OS) rate was significantly higher in BR-A(-) patients (n=94) than in BR-A(+) patients (n=28) (P=0.001), whereas there was no difference between BR-PV(-) (n=101) and BR-PV(+) patients (n=21) (P=0.257). In a multivariate analysis, the independent predictors of OS included BR-A(+) (P=0.002), lymph node metastasis (P=0.008), pathological venous invasion (P=0.003), and adjuvant chemotherapy (P=0.001). Of 39 patients who underwent venous resection, no significant difference was observed between BR-PV(-) (n=20) and BR-PV(+) patients (n=19) in resection rate, lymph node metastasis, the presence of extrapancreatic nerve invasion, recurrence rate, frequency of initial recurrence at a liver or local site, and OS. Pathological venous invasion was significantly deeper in BR-PV(+) patients. However, the depth of invasion was not associated with OS. Conclusion The definition of venous involvement in the current guidelines predicted the depth of pathological venous invasion but not OS in BRPC patients. Further prospective, randomized studies are needed to establish treatment strategies for BRPC patients with isolated venous involvement.
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2017.03.020